NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Pfizer
Novartis
Genentech, Inc.
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
InventisBio Co., Ltd